These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 20233913

  • 1. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK, Ipema HJ, Stachnik JM.
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments.
    Das C, Mendez G, Jagasia S, Labbate LA.
    Ann Clin Psychiatry; 2012 Aug; 24(3):225-39. PubMed ID: 22860242
    [Abstract] [Full Text] [Related]

  • 6. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M, Fredrickson SK, Vieweg WV.
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [Abstract] [Full Text] [Related]

  • 7. Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Hahn MK, Cohn T, Remington G.
    Ann Pharmacother; 2010 Jun; 44(7-8):1349-50; author reply 1350-1. PubMed ID: 20587740
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
    Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH.
    JAMA; 2008 Jan 09; 299(2):185-93. PubMed ID: 18182600
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A, OBD-202 Study Group.
    Diabetes Care; 2007 Jun 09; 30(6):1480-6. PubMed ID: 17363756
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Metabolic risk during antipsychotic treatment.
    Newcomer JW.
    Clin Ther; 2004 Dec 09; 26(12):1936-46. PubMed ID: 15823759
    [Abstract] [Full Text] [Related]

  • 20. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
    de Silva VA, Dayabandara M, Wijesundara H, Henegama T, Gunewardena H, Suraweera C, Hanwella R.
    J Psychopharmacol; 2015 Dec 09; 29(12):1255-61. PubMed ID: 26510448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.